Simard J, Feunteun J, Lenoir G, Tonin P, Normand T, Luu The V, Vivier A, Lasko D, Morgan K, Rouleau G A
Medical Research Council Group in Molecular Endocrinology, CHUL Research Center, Quebec, Canada.
Hum Mol Genet. 1993 Aug;2(8):1193-9. doi: 10.1093/hmg/2.8.1193.
A susceptibility gene for hereditary breast-ovarian cancer, BRCA1, has been assigned by linkage analysis to chromosome 17q21. Candidate genes in this region include EDH17B2, which encodes estradiol 17 beta-hydroxysteroid dehydrogenase II (17 beta-HSD II), and RARA, the gene for retinoic acid receptor alpha. We have typed 22 breast and breast-ovarian cancer families with eight polymorphisms from the chromosome 17q12-21 region, including two in the EDH17B2 gene. Genetic recombination with the breast cancer trait excludes RARA from further consideration as a candidate gene for BRCA1. Both BRCA1 and EDH17B2 map to a 6 cM interval (between THRA1 and D17S579) and no recombination was observed between the two genes. However, direct sequencing of overlapping PCR products containing the entire EDH17B2 gene in four unrelated affected women did not uncover any sequence variation, other than previously described polymorphisms. Mutations in the EDH17B2 gene, therefore do not appear to be responsible for the hereditary breast-ovarian cancer syndrome. Single meiotic crossovers in affected women suggest that BRCA1 is flanked by the loci RARA and D17S78.
一种遗传性乳腺癌-卵巢癌的易感基因BRCA1,已通过连锁分析定位于染色体17q21。该区域的候选基因包括EDH17B2,其编码雌二醇17β-羟类固醇脱氢酶II(17β-HSD II),以及视黄酸受体α基因RARA。我们用来自染色体17q12 - 21区域的8种多态性对22个乳腺癌和乳腺癌-卵巢癌家系进行了分型,其中包括EDH17B2基因中的两种多态性。与乳腺癌性状的基因重组排除了RARA作为BRCA1候选基因的进一步考虑。BRCA1和EDH17B2都定位于一个6厘摩的区间(在THRA1和D17S579之间),并且在这两个基因之间未观察到重组。然而,对4名无关患病女性中包含整个EDH17B2基因的重叠PCR产物进行直接测序,除了先前描述的多态性外,未发现任何序列变异。因此,EDH17B2基因的突变似乎与遗传性乳腺癌-卵巢癌综合征无关。患病女性中的单减数分裂交叉提示BRCA1两侧为RARA和D17S78位点。